Fecal calprotectin in clinical practice: A noninvasive screening tool for patients with chronic diarrhea

Journal of Clinical Gastroenterology

Volumn 46, Issue 6, 2012, Pages 504-508

  Licata, Anna ^a   Randazzo, Claudia ^a   Cappello, Maria ^a   Calvaruso, Vincenza ^a   Butera, Giuseppe ^a   Florena, Ada M ^b   Peralta, Sergio ^a   Cammà, Calogero ^a   Craxì, Antonio ^a  

^a DiBiMIS   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

chronic diarrhea; fecal calprotectin; histologic inflammation; screening tool

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; CHRONIC DIARRHEA; COLONOSCOPY; COLORECTAL POLYP; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIVERTICULOSIS; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC COLITIS; OUTPATIENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

EID: 85027917868     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318248f289     Document Type: Article

References (28)

1. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46: 1275-1280.
2. Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med. 1995;332:725-729.
3. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999; 116:1464-1486.
4. Starmans R, Fijten GH, Knottnerus JA. One year prognosis of abdominal complaints in general practice: A prospective study of patients in whom no organic cause is found. Br J Gen Pract. 1996;46:715-719.
5. Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402-408.
6. Poullis A, Foster R, Northfield TC, et al. Review article: Faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675-681.
7. Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18:756-762.
8. Voganatsi A, Panyutich A, Miyasaki KT, et al. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol. 2001;70:130-134.
9. D'Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437.
10. Roseth AG, FagerholMK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
11. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl II):II43-II47.
12. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
13. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.
14. Camilleri M, Choi MG. Review article: Irritable bowel syndrome. Alimen Pharmacol Ther. 1997;11:3-15.
15. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. New Engl J Med. 1999;340: 448-454.
16. Suffredini AF, Fantuzzi G, Badolato R, et al. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19:203-214.
17. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children. Clin Chem. 2003;49:861-867.
18. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-647.
19. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-460.
20. Kapel N. Faecal inflammatory markers in nutrition and digestive diseases in children. Arch Pediatr. 2004;11:403-405.
21. Steinbakk M, Naess-Andresen CF, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763-765.
22. Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607-609.
23. Meucci G, D'Incà R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis. 2010;42:191-195.
24. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831-2837.
25. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001; 96:2683-2687.
26. Grohmann GS, Glass RI, Pereira HG, et al. Enteric viruses and diarrhea in HIV-infected patients. New Engl J Med. 1993;329:14-20.
27. Wildt S, Nordgaard-Lassen I, Bendtsen F, et al. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19:567-574.
28. Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000;47(suppl 2):ii1-19.